Brian Fry brings extensive business development expertise to Cell One Partners, with a proven track record in the ATMP (Advanced Therapy Medicinal Products) space, as well as in biologics and vaccines. Over nearly ten years at Charles River Laboratories Biologics Solutions division, Brian led two business development teams, assisting numerous clients with their contract testing and manufacturing needs. His leadership was pivotal in navigating complex Chemistry, Manufacturing, and Controls (CMC) processes, ensuring successful project outcomes. Most recently, he spearheaded the Business Development team for the cell therapy CDMO division (formerly Cognate Bioservices) at Charles River, contributing to the commercialization of an allogeneic therapy for the European market and an autologous therapy for the US.

​

Before his tenure at Charles River, Brian spent nearly eight years at Irvine Pharma, a contract testing and aseptic fill and finish organization later acquired by Nitto Denko. There, he supported over 20 Pre-Approval Inspections (PAIs) across various modalities, showcasing his ability to manage regulatory complexities and ensure compliance. Brian's deep understanding of the biopharmaceutical landscape, combined with his strategic business development skills, makes him an invaluable asset to Cell One Partners, driving growth and fostering innovation in the field.